Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China

Eur J Dermatol. 2020 Dec 1;30(6):738-740. doi: 10.1684/ejd.2020.3908.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biological Products / adverse effects*
  • COVID-19 / complications*
  • COVID-19 / epidemiology
  • China / epidemiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Psoriasis / complications*
  • Psoriasis / drug therapy*
  • Risk Factors
  • SARS-CoV-2
  • Young Adult

Substances

  • Biological Products